Loading...
XSHE300363
Market cap1.14bUSD
Jan 14, Last price  
15.38CNY
1D
3.43%
1Q
5.20%
Jan 2017
-23.29%
IPO
45.02%
Name

Porton Pharma Solutions Ltd

Chart & Performance

D1W1MN
XSHE:300363 chart
P/E
31.44
P/S
2.29
EPS
0.49
Div Yield, %
7.47%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
25.35%
Revenues
3.67b
-47.87%
288,537,016455,834,356552,566,462689,879,030734,360,858987,255,9051,021,209,2211,326,634,0321,184,088,7671,184,863,2561,551,298,7622,071,875,4213,105,149,6297,034,801,0543,667,417,121
Net income
267m
-86.69%
30,234,06543,049,63262,395,12380,274,464100,201,387125,486,041110,394,837171,189,670107,449,932124,494,102185,550,375324,416,211523,915,3832,005,442,175266,859,527
CFO
629m
-75.47%
31,986,84635,753,79065,428,148114,209,604114,053,198121,921,427112,313,252285,331,010289,458,495193,617,828351,373,889504,374,812480,173,0872,564,418,941629,056,261
Dividend
May 29, 20240.487 CNY/sh
Earnings
May 20, 2025

Profile

Porton Pharma Solutions Ltd. manufactures and supplies small molecule active pharmaceutical ingredients and drug intermediates, dosage forms, and biologics to the pharmaceutical companies. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was founded in 2005 and is headquartered in Chongqing, China.
URL
https://www.porton.cn/
IPO date
Jan 29, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,667,417
-47.87%
7,034,801
126.55%
Cost of revenue
2,921,627
4,247,802
Unusual Expense (Income)
NOPBT
745,790
2,786,999
NOPBT Margin
20.34%
39.62%
Operating Taxes
71,045
309,383
Tax Rate
9.53%
11.10%
NOPAT
674,745
2,477,616
Net income
266,860
-86.69%
2,005,442
282.78%
Dividends
(626,568)
(105,024)
Dividend yield
4.57%
0.47%
Proceeds from repurchase of equity
(19,393)
(1)
BB yield
0.14%
0.00%
Debt
Debt current
20,025
403,521
Long-term debt
2,313,099
727,578
Deferred revenue
109,987
65,246
Other long-term liabilities
Net debt
(21,465)
(2,096,504)
Cash flow
Cash from operating activities
629,056
2,564,419
CAPEX
(1,129,869)
Cash from investing activities
(1,114,760)
Cash from financing activities
(128,537)
260,839
FCF
(532,527)
1,797,946
Balance
Cash
1,966,563
2,850,419
Long term investments
388,027
377,184
Excess cash
2,171,219
2,875,863
Stockholders' equity
3,865,630
4,863,724
Invested Capital
5,750,419
4,446,877
ROIC
13.23%
63.35%
ROCE
9.31%
37.70%
EV
Common stock shares outstanding
544,611
543,480
Price
25.15
-38.43%
40.85
-54.33%
Market cap
13,696,974
-38.31%
22,201,168
-53.69%
EV
13,974,677
20,573,832
EBITDA
1,094,902
3,046,670
EV/EBITDA
12.76
6.75
Interest
46,677
27,727
Interest/NOPBT
6.26%
0.99%